Molecular RadioTherapy (MRT)

The combination of diagnostic imaging with molecular radiotherapy (MRT)

 

Oncodesign Services offers stand-alone (SOLO) or integrated development package (DRIVE-MRT) for molecular radiotherapy (MRT), also known as targeted radioligand therapy or radiotheranostics. This offer provides biologics engineering, research-grade and cGMP chelators, bioconjugation and in-life modeling in- as well as dosimetry analyses and radiopharmaceutical clinical trial with privileged partners. With these partnerships, Oncodesign Services can offer complete discovery, development and clinical packages for developers of MRTs.

Through our bioconjugation and radiochemistry platform, a wide range of alpha, beta and gamma emitter isotopes are supported. The molecular imaging platform primarily uses PET and SPECT as modalities.

 

Example #1:

Comparison of the Anti-Tumor Activity of the Somatostatin Receptor (SST) Antagonist [177Lu]Lu-Satoreotide Tetraxetan and the Agonist [177Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST2-Positive Tumor.

 

READ THE FULL ARTICLE HERE

MRT-example1-Lu177